Real-world clinical outcomes of 5-aminolevulinic acid photodynamic therapy in patients with cervical intraepithelial neoplasia grade 1
5 affiliations
- 1School of Medicine, Southern University of Science and Technology
- 2Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital
- 3Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecologic Diseases
- 4Cheeloo College of Medicine, Shandong University
- 5Department of Obstetrics and Gynecology, Shenzhen Shenshan People’s Hospital
Abstract
Background: Cervical intraepithelial neoplasia grade 1 (CIN1) is generally managed by observation because spontaneous regression is common and progression to high-grade disease is uncommon. Nevertheless, some patients with persistent HPV infection or repeated low-grade abnormalities may elect active treatment after appropriate counseling. This study aimed to describe the clinical outcomes and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in patients with CIN1 who underwent active treatment.
Methods: This retrospective cohort study included 269 patients with CIN1 who underwent ALA-PDT at Peking University Shenzhen Hospital between July 2021 and July 2025. All patients received six sessions of ALA-PDT at intervals of 7–14 days. HPV status and ThinPrep cytologic test (TCT) results were assessed before treatment and during follow-up at 3 months (± 1 month) and, in some patients, at 6 months (± 1 month) after treatment. HPV clearance, cytological improvement, and treatment-related adverse events were analyzed.
Results: Among the 266 HPV-positive patients, 155 patients (58.27%) had a negative HPV result at the predefined 3-month follow-up. At 3 months, 205 of 247 patients (83.00%) with available cytological assessment had NILM cytology. No serious adverse events were observed during treatment or follow-up.
Conclusions: In this retrospective cohort study, HPV negativity and improved cytological findings were observed during follow-up after ALA-PDT, together with an acceptable safety profile and no serious adverse events.
Related
- Case Report: Successful treatment of verruciform acanthotic vulvar intraepithelial neoplasia with 5-aminolevulinic acid photodynamic therapy.
- Optimal number of 5-aminolevulinic acid photodynamic therapy sessions for cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: a retrospective cohort study
- Methyl aminolevulinate-PpIX mediated fluorescence-guided mapping of high-grade vulvar intraepithelial neoplasia: a pilot prospective clinical trial (PhotoDiVin).
- Complementary cytotoxicity of GD2-targeted photoimmunotherapy and 5-aminolevulinic acid photodynamic therapy in neuroblastoma and osteosarcoma
- Diagnostic accuracy of a systematic approach using Swedescore versus conventional colposcopy for the detection of cervical intraepithelial neoplasia grade 2 or worse: A multicenter, non‐randomized clinical study
BibTeX
@article{fan2026realworld,
title = {{Real-world clinical outcomes of 5-aminolevulinic acid photodynamic therapy in patients with cervical intraepithelial neoplasia grade 1}},
author = {Tianci Fan and Lina Geng and Guanwen Gao and Zixun Long and Degao Liu and Yunfei Wang and Changzhong Li},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1896229},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1896229/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world clinical outcomes of 5-aminolevulinic acid photodynamic therapy in patients with cervical intraepithelial neoplasia grade 1
AU - Tianci Fan
AU - Lina Geng
AU - Guanwen Gao
AU - Zixun Long
AU - Degao Liu
AU - Yunfei Wang
AU - Changzhong Li
PY - 2026
DA - 2026/10/21
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1896229
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1896229/full
AB - Background: Cervical intraepithelial neoplasia grade 1 (CIN1) is generally managed by observation because spontaneous regression is common and progression to high-grade disease is uncommon. Nevertheless, some patients with persistent HPV infection or repeated low-grade abnormalities may elect active treatment after appropriate counseling. This study aimed to describe the clinical outcomes and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in patients with CIN1 who underwent active treatment. Methods: This retrospective cohort study included 269 patients with CIN1 who underwent ALA-PDT at Peking University Shenzhen Hospital between July 2021 and July 2025. All patients received six sessions of ALA-PDT at intervals of 7–14 days. HPV status and ThinPrep cytologic test (TCT) results were assessed before treatment and during follow-up at 3 months (± 1 month) and, in some patients, at 6 months (± 1 month) after treatment. HPV clearance, cytological improvement, and treatment-related adverse events were analyzed. Results: Among the 266 HPV-positive patients, 155 patients (58.27%) had a negative HPV result at the predefined 3-month follow-up. At 3 months, 205 of 247 patients (83.00%) with available cytological assessment had NILM cytology. No serious adverse events were observed during treatment or follow-up. Conclusions: In this retrospective cohort study, HPV negativity and improved cytological findings were observed during follow-up after ALA-PDT, together with an acceptable safety profile and no serious adverse events.
SN - 2234-943X
ER -